CCR2 and neoplasm: Xenografts were then analyzed for changes in growth and stromal reactivity, which correlates with invasiveness.43 Compared to control xenografts, Merestinib treatment did not significantly inhibit the growth of breast xenografts, while CCR2-KO alone significantly reduced the growth of breast xenografts by 68%, consistent with previous studies.33 CCR2-KO combined with Merestinib treatment resulted in the most significant inhibition in the growth of breast xenografts, with a 74% reduction in tumor volume.